Trial Profile

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants with HeFH And/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2025 According to a NewAmsterdam Pharma media release, data from the trial were presented during a Developing Topics oral session at the 2025 Alzheimers Association International Conference (AAIC) in Toronto
30 Jul 2025 Results presented in the NewAmsterdam Pharma Media Release.
22 Jul 2025 According to a NewAmsterdam Pharma media release, the company will host a live webcast and conference call at 10:00 a.m. ET on July 30, 2025 to review the full AD biomarker data presented at AAIC.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com